Erik A. Imel

7.9k total citations · 3 hit papers
100 papers, 4.2k citations indexed

About

Erik A. Imel is a scholar working on Nephrology, Oncology and Genetics. According to data from OpenAlex, Erik A. Imel has authored 100 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Nephrology, 37 papers in Oncology and 27 papers in Genetics. Recurrent topics in Erik A. Imel's work include Parathyroid Disorders and Treatments (66 papers), Bone health and treatments (36 papers) and Magnesium in Health and Disease (19 papers). Erik A. Imel is often cited by papers focused on Parathyroid Disorders and Treatments (66 papers), Bone health and treatments (36 papers) and Magnesium in Health and Disease (19 papers). Erik A. Imel collaborates with scholars based in United States, Canada and Australia. Erik A. Imel's co-authors include Michael J. Econs, Thomas O. Carpenter, Karl Insogna, Siu L. Hui, Munro Peacock, Suzanne M. Jan de Beur, Ingrid A. Holm, Shoji Ichikawa, Andrea H. Sorenson and Alison Skrinar and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Erik A. Imel

95 papers receiving 4.2k citations

Hit Papers

A clinician's guide to X-linked hypophosphatemia 2011 2026 2016 2021 2011 2018 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A clinician's guide to X-linked hypophosphatemia
    2011 412 citations Thomas O. Carpenter, Erik A. Imel et al. Journal of Bone and Mineral Research profile →
  2. Burosumab Therapy in Children with X-Linked Hypophosphatemia
    2018 321 citations Thomas O. Carpenter, Michael P. Whyte et al. profile →
  3. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia
    2020 179 citations Michael J. Econs, Munro Peacock et al. profile →

Peers

Erik A. Imel
Barbara Gales United States
Beatriz D. Kuizon United States
Jessica Pepe Italy
Elvira Fernández Spain
Janice L. Pasieka Canada
D.L. Andress United States
Gema Ariceta Spain
Cristina Eller-Vainicher Italy
Tatsuya Suwabe Japan
Barbara Gales United States
Erik A. Imel
Citations per year, relative to Erik A. Imel Erik A. Imel (= 1×) peers Barbara Gales

Countries citing papers authored by Erik A. Imel

Since Specialization
Citations

This map shows the geographic impact of Erik A. Imel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A. Imel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A. Imel more than expected).

Fields of papers citing papers by Erik A. Imel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A. Imel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A. Imel. The network helps show where Erik A. Imel may publish in the future.

Co-authorship network of co-authors of Erik A. Imel

This figure shows the co-authorship network connecting the top 25 collaborators of Erik A. Imel. A scholar is included among the top collaborators of Erik A. Imel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik A. Imel. Erik A. Imel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Warden, Stuart J., Robyn K. Fuchs, Keith G. Avin, et al.. (2025). Reference Data and Predictors of HR‐pQCT‐Derived Muscle Density and Its Prediction of Physical Performance. Journal of Cachexia Sarcopenia and Muscle. 16(4). e70029–e70029. 2 indexed citations
2.
Imel, Erik A., et al.. (2024). Osteopetrosis in the pediatric patient: what the radiologist needs to know. Pediatric Radiology. 54(7). 1105–1115.
3.
Brown, C., et al.. (2024). 668 Fat mass increases and lean mass decreases during 24 months of CFTR modulator therapy. Journal of Cystic Fibrosis. 23. S373–S374. 1 indexed citations
4.
Sosa, Branden, He S. Yang, Michelle M. McDonald, et al.. (2024). The performance of artificial intelligence chatbot large language models to address skeletal biology and bone health queries. Journal of Bone and Mineral Research. 39(2). 106–115. 14 indexed citations
5.
Gottesman, Gary S., Melissa Wallace, Peter A. Smith, et al.. (2024). 6820 Assessing The Efficacy And Safety Of Setrusumab For Osteogenesis Imperfecta: Updated Phase 2 Data From The Phase 2/3 Orbit Study. Journal of the Endocrine Society. 8(Supplement_1). 2 indexed citations
6.
Polgreen, Lynda E., Erik A. Imel, & Michael J. Econs. (2023). Autosomal dominant osteopetrosis. Bone. 170. 116723–116723. 10 indexed citations
7.
Linglart, Agnès, Erik A. Imel, Michael P. Whyte, et al.. (2021). Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 107(3). 813–824. 53 indexed citations
8.
Daugherty, Sean C., Nicole L. Miller, Thomas O. Carpenter, et al.. (2021). Novel PHEX gene locus‐specific database: Comprehensive characterization of vast number of variants associated with X‐linked hypophosphatemia (XLH). Human Mutation. 43(2). 143–157. 27 indexed citations
9.
Imel, Erik A., et al.. (2019). FGF23 and Associated Disorders of Phosphate Wasting. PMC. 30 indexed citations
10.
Guandique, Cristian F., et al.. (2019). Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. PMC.
11.
Zhang, Xiaoping, Erik A. Imel, Mary D. Ruppe, et al.. (2016). Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia. Publisher. 1 indexed citations
12.
Cabrera, Susanne M., et al.. (2015). Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients. PMC. 6 indexed citations
13.
Imel, Erik A. & Thomas O. Carpenter. (2015). A Practical Clinical Approach to Paediatric Phosphate Disorders. Endocrine development. 28. 134–161. 7 indexed citations
14.
Imel, Erik A., Xiaoping Zhang, Mary D. Ruppe, et al.. (2015). Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal of Clinical Endocrinology & Metabolism. 100(7). 2565–2573. 114 indexed citations
15.
Imel, Erik A., et al.. (2015). Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action. Current Osteoporosis Reports. 13(2). 78–87. 20 indexed citations
16.
Ruppe, Mary D., Xiao–Ping Zhang, Erik A. Imel, et al.. (2014). Assessment of Quality of Life Data After 4 Monthly S.C. Doses of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia. 82. 1 indexed citations
17.
Imel, Erik A., Munro Peacock, Amie K. Gray, et al.. (2011). Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. The Journal of Clinical Endocrinology & Metabolism. 96(11). 3541–3549. 219 indexed citations
18.
Imel, Erik A., Linda A. DiMeglio, Siu L. Hui, Thomas O. Carpenter, & Michael J. Econs. (2010). Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. The Journal of Clinical Endocrinology & Metabolism. 95(4). 1846–1850. 111 indexed citations
19.
Ichikawa, Shoji, Geneviève Baujat, Aksel Seyahi, et al.. (2010). Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. American Journal of Medical Genetics Part A. 152A(4). 896–903. 75 indexed citations
20.
Ichikawa, Shoji, Erik A. Imel, Xijie Yu, et al.. (2007). A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. Journal of Clinical Investigation. 117(9). 2684–2691. 336 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Gales Breakdown of academic impact, for papers by Beatriz D. Kuizon Breakdown of academic impact, for papers by Jessica Pepe Breakdown of academic impact, for papers by Elvira Fernández Breakdown of academic impact, for papers by Janice L. Pasieka Breakdown of academic impact, for papers by D.L. Andress Breakdown of academic impact, for papers by Gema Ariceta Breakdown of academic impact, for papers by Cristina Eller-Vainicher Breakdown of academic impact, for papers by Tatsuya Suwabe
Rankless by CCL
2026